Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Report results of patient-reported health-related quality of life (HRQoL) and symptoms from phase III KEYNOTE-006 study of pembrolizumab versus ipilimumab in patients with ipilimumab-naive advanced melanoma.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Eur. J. Cancer

Title: European journal of cancer (Oxford, England : 1990)

Publisher: Elsevier BV

ISSN (Electronic): 1879-0852

ISSN (Print): 0959-8049

Publication date (Electronic): November 2017

Volume: 86

Affiliations

[1 ] Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Ave, T2-041, Toronto, ON, M4N 3M5, Canada. Electronic address: teresa.petrella@sunnybrook.ca.

[2 ] Gustave Roussy and Université Paris-Sud, 114 Rue Edouard Vaillant, 94800 Villejuif, France. Electronic address: caroline.robert@gustaveroussy.fr.

[3 ] Medical University of Graz, Auenbruggerpl. 2, 8036 Graz, Graz, Austria. Electronic address: erika.richtig@medunigraz.at.

[4 ] Segal Cancer Centre, Jewish General Hospital, Rossy Cancer Network, and McGill University, 3755 Ch de la Côte-Sainte-Catherine, Montreal, QC, H3T 1E2, Canada. Electronic address: wilsonmiller@gmail.com.

[5 ] Karolinska Institute, Solnavägen 1, 171 77 Solna, Stockholm, Sweden. Electronic address: giuseppe.masucci@ki.se.

[6 ] Princess Alexandra Hospital and The University of Queensland, 199 Ipswich Rd, Woolloongabba, Brisbane, QLD 4102, Australia. Electronic address: euan.walpole@health.qld.gov.au.

[7 ] APHP, Dermatology and CIC, Université Paris Diderot, Hôpital Saint-Louis, 1 Avenue Claude Vellefaux, 75010 Paris, France. Electronic address: celeste.lebbe@aphp.fr.

[8 ] Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Birmingham B15 2TH, UK. Electronic address: N.M.Steven@bham.ac.uk.

[9 ] The Churchill Hospital and The University of Oxford, Old Rd, Headington, Oxford OX3 7LE, UK. Electronic address: mark.middleton@oncology.ox.ac.uk.

[10 ] Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA. Electronic address: darcy_hille@merck.com.

[11 ] Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA. Electronic address: wei.zhou2@merck.com.

[12 ] Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA. Electronic address: nageatte.ibrahim@merck.com.

[13 ] Olivia Newton-John Cancer Research Institute, Austin Health, School of Cancer Medicine, La Trobe University, 145 Studley Road, Heidelberg VIC 3084, Melbourne, Australia. Electronic address: jonathan.cebon@onjcri.org.au.

Article

Publisher Item ID: S0959-8049(17)31257-1

DOI: 10.1016/j.ejca.2017.08.032

PubMed ID: 28987768

SO-VID: 8cc7168f-741d-4007-bb1d-f4d27ef28485

History

Keywords: Advanced melanoma,EORTC QLQ-C30,Health-related quality of life,KEYNOTE-006,Patient-reported outcomes,Pembrolizumab

Data availability:

Keywords: Advanced melanoma, EORTC QLQ-C30, Health-related quality of life, KEYNOTE-006, Patient-reported outcomes, Pembrolizumab

Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.

Read this article at

Abstract

Related collections

Procedural speed in criminal law

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 503

Cited by 29